167 related articles for article (PubMed ID: 35712255)
1. Novel Targeting of DNA Methyltransferase Activity Inhibits Ewing Sarcoma Cell Proliferation and Enhances Tumor Cell Sensitivity to DNA Damaging Drugs by Activating the DNA Damage Response.
Cristalli C; Manara MC; Valente S; Pellegrini E; Bavelloni A; De Feo A; Blalock W; Di Bello E; Piñeyro D; Merkel A; Esteller M; Tirado OM; Mai A; Scotlandi K
Front Endocrinol (Lausanne); 2022; 13():876602. PubMed ID: 35712255
[TBL] [Abstract][Full Text] [Related]
2. A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy.
Manara MC; Valente S; Cristalli C; Nicoletti G; Landuzzi L; Zwergel C; Mazzone R; Stazi G; Arimondo PB; Pasello M; Guerzoni C; Picci P; Nanni P; Lollini PL; Mai A; Scotlandi K
Mol Cancer Ther; 2018 Sep; 17(9):1881-1892. PubMed ID: 29959201
[TBL] [Abstract][Full Text] [Related]
3. Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Sampson VB; Vetter NS; Kamara DF; Collier AB; Gresh RC; Kolb EA
PLoS One; 2015; 10(11):e0142704. PubMed ID: 26571493
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1.
Huertas-Martínez J; Court F; Rello-Varona S; Herrero-Martín D; Almacellas-Rabaiget O; Sáinz-Jaspeado M; Garcia-Monclús S; Lagares-Tena L; Buj R; Hontecillas-Prieto L; Sastre A; Azorin D; Sanjuan X; López-Alemany R; Moran S; Roma J; Gallego S; Mora J; García Del Muro X; Giangrande PH; Peinado MA; Alonso J; de Alava E; Monk D; Esteller M; Tirado OM
Cancer Lett; 2017 Feb; 386():196-207. PubMed ID: 27894957
[TBL] [Abstract][Full Text] [Related]
5. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.
Lee HJ; Yoon C; Schmidt B; Park DJ; Zhang AY; Erkizan HV; Toretsky JA; Kirsch DG; Yoon SS
Mol Cancer Ther; 2013 Nov; 12(11):2591-600. PubMed ID: 23966622
[TBL] [Abstract][Full Text] [Related]
6. CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin.
Guerzoni C; Fiori V; Terracciano M; Manara MC; Moricoli D; Pasello M; Sciandra M; Nicoletti G; Gellini M; Dominici S; Chiodoni C; Fornasari PM; Lollini PL; Colombo MP; Picci P; Cianfriglia M; Magnani M; Scotlandi K
Clin Cancer Res; 2015 Jan; 21(1):146-56. PubMed ID: 25501132
[TBL] [Abstract][Full Text] [Related]
7. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
[TBL] [Abstract][Full Text] [Related]
9. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
González I; Andreu EJ; Panizo A; Inogés S; Fontalba A; Fernández-Luna JL; Gaboli M; Sierrasesúmaga L; Martín-Algarra S; Pardo J; Prósper F; de Alava E
Clin Cancer Res; 2004 Jan; 10(2):751-61. PubMed ID: 14760098
[TBL] [Abstract][Full Text] [Related]
10. Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.
Dowless M; Lowery CD; Shackleford T; Renschler M; Stephens J; Flack R; Blosser W; Gupta S; Stewart J; Webster Y; Dempsey J; VanWye AB; Ebert P; Iversen P; Olsen JB; Gong X; Buchanan S; Houghton P; Stancato L
Clin Cancer Res; 2018 Dec; 24(23):6028-6039. PubMed ID: 30131386
[TBL] [Abstract][Full Text] [Related]
11. XI-006 induces potent p53-independent apoptosis in Ewing sarcoma.
Pishas KI; Adwal A; Neuhaus SJ; Clayer MT; Farshid G; Staudacher AH; Callen DF
Sci Rep; 2015 Jun; 5():11465. PubMed ID: 26095524
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
Vormoor B; Curtin NJ
Curr Opin Oncol; 2014 Jul; 26(4):428-33. PubMed ID: 24840521
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
[TBL] [Abstract][Full Text] [Related]
14. The Ewing Family of Tumors Relies on BCL-2 and BCL-X
Heisey DAR; Lochmann TL; Floros KV; Coon CM; Powell KM; Jacob S; Calbert ML; Ghotra MS; Stein GT; Maves YK; Smith SC; Benes CH; Leverson JD; Souers AJ; Boikos SA; Faber AC
Clin Cancer Res; 2019 Mar; 25(5):1664-1675. PubMed ID: 30348635
[TBL] [Abstract][Full Text] [Related]
15. EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.
Iniguez AB; Stolte B; Wang EJ; Conway AS; Alexe G; Dharia NV; Kwiatkowski N; Zhang T; Abraham BJ; Mora J; Kalev P; Leggett A; Chowdhury D; Benes CH; Young RA; Gray NS; Stegmaier K
Cancer Cell; 2018 Feb; 33(2):202-216.e6. PubMed ID: 29358035
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.
Palii SS; Van Emburgh BO; Sankpal UT; Brown KD; Robertson KD
Mol Cell Biol; 2008 Jan; 28(2):752-71. PubMed ID: 17991895
[TBL] [Abstract][Full Text] [Related]
17. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
18. Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors.
Loganathan SN; Tang N; Holler AE; Wang N; Wang J
Mol Cancer Ther; 2019 May; 18(5):929-936. PubMed ID: 30926641
[TBL] [Abstract][Full Text] [Related]
19. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
20. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma.
Heske CM; Davis MI; Baumgart JT; Wilson K; Gormally MV; Chen L; Zhang X; Ceribelli M; Duveau DY; Guha R; Ferrer M; Arnaldez FI; Ji J; Tran HL; Zhang Y; Mendoza A; Helman LJ; Thomas CJ
Clin Cancer Res; 2017 Dec; 23(23):7301-7311. PubMed ID: 28899971
[No Abstract] [Full Text] [Related]
[Next] [New Search]